GIST
MCID: GST019
MIFTS: 73

Gastrointestinal Stromal Tumor (GIST) malady

Categories: Genetic diseases, Rare diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Gastrointestinal Stromal Tumor

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 27GTR, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Gastrointestinal Stromal Tumor:

Name: Gastrointestinal Stromal Tumor 52 11 24 25 54 70 12 50 13
Gist 11 48 24 25 54 70 13
Gastrointestinal Stromal Sarcoma 48 25 54 68
Gastrointestinal Stromal Tumors 48 27 39 68
Paraganglioma and Gastric Stromal Sarcoma 68
Gastrointestinal Stromal Tumor, Familial 52
 
Gastrointestinal Stromal Tumor, Somatic 52
Stromal Tumor of Gastrointestinal Tract 11
Gastrointestinal Stromal Neoplasm 25
Plexosarcoma 68
Gant 11

Characteristics:

Orphanet epidemiological data:

54
gastrointestinal stromal tumor:
Inheritance: Autosomal dominant,Not applicable; Prevalence: 1-5/10000 (Europe),1-5/10000 (Sweden); Age of onset: Adolescent,Adult,Childhood

HPO:

64
gastrointestinal stromal tumor:
Inheritance: autosomal dominant inheritance, sporadic

Classifications:



External Ids:

OMIM52 606764
Disease Ontology11 DOID:9253
MeSH39 D046152
NCIt45 C3868
Orphanet54 ORPHA44890
MESH via Orphanet40 D046152
UMLS via Orphanet69 C0238198
ICD10 via Orphanet31 C26.9
MedGen37 C0238198

Summaries for Gastrointestinal Stromal Tumor

About this section
OMIM:52 Gastrointestinal stromal tumors are mesenchymal tumors found in the gastrointestinal tract that originate from the... (606764) more...

MalaCards based summary: Gastrointestinal Stromal Tumor, also known as GIST, is related to paraganglioma and gastric stromal sarcoma and desmoid tumor, and has symptoms including Array, Array and Array. An important gene associated with Gastrointestinal Stromal Tumor is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are Osteoblast Signaling and Gefitinib Pathway, Pharmacokinetics. Affiliated tissues include small intestine, colon and endothelial, and related mouse phenotypes are Increased senescence-associated beta-galactosidase protein expression after pRB stimulation and Decreased viability.

Genetics Home Reference:25 A gastrointestinal stromal tumor (GIST) is a type of tumor that occurs in the gastrointestinal tract, most commonly in the stomach or small intestine. The tumors are thought to grow from specialized cells found in the gastrointestinal tract called interstitial cells of Cajal (ICCs) or precursors to these cells. GISTs are usually found in adults between ages 40 and 70; rarely, children and young adults develop these tumors. The tumors can be cancerous (malignant) or noncancerous (benign).

NIH Rare Diseases:48 Gastrointestinal stromal tumors are a type of soft tissue sarcoma (tumor) that usually begins in cells in the wall of the stomach, intestines, or rectum. these tumors may be noncancerous or cancerous. they can affect adults, adolescents, or children.  it is estimated that around 5,000 new cases of gastrointestinal stromal tumors are diagnosed in the united states each year. last updated: 4/27/2010

UniProtKB/Swiss-Prot:70 Gastrointestinal stromal tumor: Common mesenchymal neoplasms arising in the gastrointestinal tract, most often in the stomach. They are histologically, immunohistochemically, and genetically different from typical leiomyomas, leiomyosarcomas, and schwannomas. Most GISTs are composed of a fairly uniform population of spindle-shaped cells. Some tumors are dominated by epithelioid cells or contain a mixture of spindle and epithelioid morphologies. Primary GISTs in the gastrointestinal tract commonly metastasize in the omentum and mesenteries, often as multiple nodules. However, primary tumors may also occur outside of the gastrointestinal tract, in other intra-abdominal locations, especially in the omentum and mesentery.

Wikipedia:71 Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the... more...

Related Diseases for Gastrointestinal Stromal Tumor

About this section

Diseases related to Gastrointestinal Stromal Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 305)
idRelated DiseaseScoreTop Affiliating Genes
1paraganglioma and gastric stromal sarcoma33.1SDHB, SDHC, SDHD
2desmoid tumor30.6ACTC1, S100B, VIM
3pheochromocytoma30.2ENO2, SDHA, SDHB, SDHC, SDHD
4intestinal obstruction30.2ACTC1, DES, NTRK3, VIM
5adenosarcoma29.7ACTC1, DES, ENO2, KIT, PDGFRA, PDGFRB
6plexosarcoma10.9
713q12.3 microdeletion syndrome10.4ACTC1, DES, VIM
8neurofibroma of gallbladder10.4CD34, KIT
9gallbladder leiomyosarcoma10.4CD34, KIT
10carbon monoxide-induced parkinsonism10.4ACTC1, DES, KIT
11lymphomatoid papulosis10.4ACTC1, VIM
12invasive mole10.4KIT, PDGFRA, S100B
13marfanoid hypermobility syndrome10.4DES, KIT, VIM
14liver angiosarcoma10.4DES, KIT, VIM
15osteomyelitis10.4ACTC1, DES, VIM
16congenital myasthenic syndrome10.4ACTC1, DES, VIM
17urethral cancer10.4ACTC1, DES, VIM
18inflammatory linear verrucous epidermal nevus10.4DES, VIM
19biemond syndrome10.4ACTC1, DES, VIM
20biliary papillomatosis10.4DES, S100B, VIM
21oral erosive lichen10.4ACTC1, DES
22male urethral cancer10.4ACTC1, DES, VIM
23testis sarcoma10.4CD34, DES, KIT
24cavernous sinus meningioma10.4DES, S100B, VIM
25lupus - neurological sequelae10.4S100B, VIM
26coronary stenosis10.4ACTC1, DES, VIM
27vulvar squamous papilloma10.4DES, S100B, VIM
28conjunctival cancer10.4ACTC1, S100B, VIM
29chest wall parachordoma10.4ACTC1, CD34, VIM
30stomach diverticulosis10.4KIT, S100B, VIM
31omodysplasia 210.4ACTC1, DES, VIM
32hypogonadotropic hypogonadism-retinitis pigmentosa syndrome10.4ACTC1, S100B, VIM
33dfnb110.4KIT, PDGFRA, PDGFRB
34kahrizi syndrome10.4KIT, PDGFRA, PDGFRB
35lung benign neoplasm10.4ACTC1, DES, VIM
36speech disorder10.4CD34, KIT
37episodic ataxia10.4ACTC1, CD34, DES
38fibrosarcoma10.4CD34, KIT, PDGFRA
39pustulosis palmaris et plantaris10.4ACTC1, DES, KIT, PDGFRA
40orthostatic proteinuria10.4ACTC1, DES, VIM
41gangliosidosis gm110.4ACTC1, DES, KIT
42sebaceous adenoma10.4ACTC1, DES, KIT, VIM
43pilar sheath acanthoma10.4ACTC1, DES, KIT, VIM
44fitz-hugh-curtis syndrome10.4ACTC1, DES, KIT, VIM
45intravenous leiomyomatosis10.4SDHB, SDHC, SDHD
46adult endodermal sinus tumor10.4DES, ENO2, VIM
47scirrhous adenocarcinoma10.4ACTC1, DES, VIM
48rectum leiomyoma10.4ENO2, KIT, PDGFRA
49endocervical adenocarcinoma10.4SDHB, SDHC, SDHD
50myoma10.4ACTC1, DES, S100B, VIM

Graphical network of the top 20 diseases related to Gastrointestinal Stromal Tumor:



Diseases related to gastrointestinal stromal tumor

Symptoms & Phenotypes for Gastrointestinal Stromal Tumor

About this section

Symptoms by clinical synopsis from OMIM:

606764

Clinical features from OMIM:

606764

Human phenotypes related to Gastrointestinal Stromal Tumor:

 54 64 (show all 22)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 skin rash64 54 Occasional (29-5%) HP:0000988
2 abnormality of the liver64 54 Occasional (29-5%) HP:0001392
3 anemia64 54 Occasional (29-5%) HP:0001903
4 dysphagia64 54 Frequent (79-30%) HP:0002015
5 nausea and vomiting64 54 Frequent (79-30%) HP:0002017
6 constipation64 54 Frequent (79-30%) HP:0002019
7 gastrointestinal hemorrhage64 54 Frequent (79-30%) HP:0002239
8 intestinal obstruction64 54 Frequent (79-30%) HP:0005214
9 neoplasm of the stomach64 54 Very frequent (99-80%) HP:0006753
10 neoplasm of the gastrointestinal tract54 Occasional (29-5%)
11 irregular hyperpigmentation64 54 Occasional (29-5%) HP:0007400
12 fatigue64 54 Frequent (79-30%) HP:0012378
13 sarcoma64 54 Very frequent (99-80%) HP:0100242
14 neoplasm of the colon64 54 Occasional (29-5%) HP:0100273
15 gastrointestinal stroma tumor64 54 Very frequent (99-80%) HP:0100723
16 neoplasm of the rectum64 54 Occasional (29-5%) HP:0100743
17 esophageal neoplasm64 54 Occasional (29-5%) HP:0100751
18 neoplasm of the small intestine64 54 Occasional (29-5%) HP:0100833
19 hyperpigmentation of the skin64 HP:0000953
20 urticaria64 HP:0001025
21 neurofibromas64 HP:0001067
22 large hands64 HP:0001176

GenomeRNAi Phenotypes related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00230-A-210.8FLT3, KIT, PRKCQ
2GR00381-A-18.3FLT3, HSP90AA1, NTRK3, PDGFRA, PDGFRB, PRKCQ

MGI Mouse Phenotypes related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

41 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.8CD34, FLT3, KIT, KITLG, PDGFRA, PRKCQ
2MP:00030129.5FLT3, KIT, MTHFR, NTRK3, PDGFRA, PRKCQ
3MP:00053699.5ACTC1, DES, ETV1, KIT, PDGFRA, PDGFRB
4MP:00028739.4ACTC1, ETV1, KIT, NTRK3, PDGFRA, PDGFRB
5MP:00053869.1DES, ENO2, ETV1, HSP90AA1, KIT, NTRK3
6MP:00053799.1FLT3, HSP90AA1, KIT, KITLG, PDGFRA, PDGFRB
7MP:00053859.0ACTC1, DES, KIT, KITLG, NTRK3, PDGFRA
8MP:00053788.9ACTC1, ENO2, ETV1, FLT3, KIT, KITLG
9MP:00053768.6ACTC1, CD34, DES, FLT3, KIT, KITLG
10MP:00053848.6ACTC1, CD34, DES, ENO2, ETV1, FLT3
11MP:00036318.6ENO2, ETV1, KIT, KITLG, MTHFR, NTRK3
12MP:00107688.2ACTC1, DES, ETV1, FLT3, HSP90AA1, KIT

Drugs & Therapeutics for Gastrointestinal Stromal Tumor

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Gleevec16 44 IMATINIB MESYLATE Novartis May 2001
FDA Label: Gleevec
Disease/s that Drug Treats:chronic myeloid leukemia/Gastrointestinal stromal tumors (GISTs)
Indications and Usage:16 Gleevec™ (imatinib mesylate) is indicated for the treatment of newly diagnosed adultpatients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronicphase. Follow-up is limited. Page 10Gleevec is also indicated for the treatment of patients with Philadelphia chromosomepositive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronicphase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment ofpediatric patients with Ph+ chronic phase CML whose disease has recurred after stem celltransplant or who are resistant to interferon alpha therapy. There are no controlled trialsdemonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.Gleevec is also indicated for the treatment of patients with Kit (CD117) positiveunresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (SeeCLINICAL STUDIES: Gastrointestinal Stromal Tumors.) The effectiveness of Gleevec inGIST is based on objective response rate (see CLINICAL STUDIES). There are no controlledtrials demonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.
DrugBank Targets:14 1. BCR/ABL fusion protein isoform X9;2. Mast/stem cell growth factor receptor Kit;3. RET proto-oncogene;4. High affinity nerve growth factor receptor;5. Macrophage colony-stimulating factor 1 receptor;6. Platelet-derived growth factor receptor alpha;7. Epithelial discoidin domain-containing receptor 1;8. Tyrosine-protein kinase ABL1;9. Platelet-derived growth factor receptor beta
Mechanism of Action:16 
Target: protein-tyrosine kinase
Action: inhibitor
FDA: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosinekinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosomeabnormality in chronic myeloid leukemia (CML). It inhibits proliferation and inducesapoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphiachromosome positive chronic myeloid leukemia. In colony formation assays using ex vivoperipheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positivecolonies from CML patients.In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as wellas Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derivedgrowth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- andSCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis ingastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
2
Stivarga16 44 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
FDA Label: Stivarga
Disease/s that Drug Treats:gastrointestinal stromal tumor/ metastatic colorectal cancer
Indications and Usage:16 Stivarga is a kinase inhibitor indicated for the treatment of patients with: Metastatic colorectal cancer (CRC) who have been previously treated withfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGFtherapy, and, if KRAS wild type, an anti-EGFR therapy. (1.1) Locally advanced, unresectable or metastatic gastrointestinal stromal tumor(GIST) who have been previously treated with imatinib mesylate andsunitinib malate. (1.2)
DrugBank Targets:14 1. Proto-oncogene tyrosine-protein kinase receptor Ret;2. Vascular endothelial growth factor receptor 1;3. Vascular endothelial growth factor receptor 2;4. Vascular endothelial growth factor receptor 3;5. Mast/stem cell growth factor receptor Kit;6. Platelet-derived growth factor receptor alpha;7. Platelet-derived growth factor receptor beta;8. Fibroblast growth factor receptor 1;9. Fibroblast growth factor receptor 2;10. Angiopoietin-1 receptor;11. Discoidin domain-containing receptor 2;12. High affinity nerve growth factor receptor;13. Ephrin type-A receptor 2;14. RAF proto-oncogene serine/threonine-protein kinase;15. Serine/threonine-protein kinase B-raf;16. Mitogen-activated protein kinase 11;17. Tyrosine-protein kinase FRK;18. Tyrosine-protein kinase ABL1
Mechanism of Action:16 
Target: RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl kinases
Action: inhibitor
FDA: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normalcellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumormicroenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 andM-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib thathave been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model,and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some forhuman colorectal carcinoma.
3
Sutent16 44 SUNITINIB MALATE Pfizer May 2011/ January 2006
FDA Label: Sutent
Disease/s that Drug Treats:pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:16 SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on orintolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors(pNET) in patients with unresectable locally advanced or metastaticdisease. (1.3)
DrugBank Targets:14 1. Platelet-derived growth factor receptor beta;2. Vascular endothelial growth factor receptor 1;3. Mast/stem cell growth factor receptor Kit;4. Vascular endothelial growth factor receptor 2;5. Vascular endothelial growth factor receptor 3;6. Receptor-type tyrosine-protein kinase FLT3;7. Macrophage colony-stimulating factor 1 receptor;8. Platelet-derived growth factor receptor alpha
Mechanism of Action:16 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which areimplicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib wasevaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitorof platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical andcellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primarymetabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR, VEGFR2, KIT) in tumor xenograftsexpressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/orinhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibitgrowth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibitPDGFR- and VEGFR2-dependent tumor angiogenesis in vivo.
4
Votrient16 44 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009
FDA Label: Votrient
Disease/s that Drug Treats:soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:16 VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: advanced renal cell carcinoma. (1) advanced soft tissue sarcoma who have received prior chemotherapy. (1)Limitation of Use: The efficacy of VOTRIENT for the treatment of patientswith adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has notbeen demonstrated.
DrugBank Targets:14 1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3;4. Platelet-derived growth factor receptor alpha;5. Platelet-derived growth factor receptor beta;6. Mast/stem cell growth factor receptor Kit;7. Fibroblast growth factor receptor 3;8. Tyrosine-protein kinase ITK/TSK;9. Fibroblast growth factor 1;10. SH2B adapter protein 3
Mechanism of Action:16 
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factorreceptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-αand -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), andtransmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibitedligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo,pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis ina mouse model, and the growth of some human tumor xenografts in mice.

Drugs for Gastrointestinal Stromal Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 204)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Oxaliplatinapproved, investigationalPhase 4, Phase 1146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
2
Sunitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1510341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
3
Midazolamapproved, illicitPhase 4, Phase 172359467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
 
Dormicum
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
4
EverolimusapprovedPhase 4, Phase 1, Phase 21940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
5
Sirolimusapproved, investigationalPhase 4, Phase 1, Phase 2194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
6
Esomeprazoleapproved, investigationalPhase 4333161796-78-7, 119141-88-74594, 9579578
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(-)-omeprazole
(S)-(-)-Omeprazole
(S)-(−)-omeprazole
(S)-Omeprazole
(S)-omeprazole
(s)-omeprazole
(−)-omeprazole
119141-88-7
119141-89-8
131959-78-9
172964-80-6
193469-77-1
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
326602-80-6
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
6-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
73590-58-6
AC-401
AC1L1IIJ
AGI-010
AKOS005066653
AULCER
Antra
Antra MUPS
Audazol
Axagon
BIDD:GT0020
BIDD:GT0189
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
Belmazol
Bio-0888
C07324
CAS-73590-58-6
CCRIS 7099
CHEBI:50275
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CID9568614
CID9579578
CPD000058847
Ceprandal
D00455
D07917
DB00338
DB00736
DM-3458
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
Esomeprazol
Esomeprazole
Esomeprazole (INN)
Esomeprazole Sodium
Esomeprazole [INN:BAN]
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168-68
H 168/68
H-168/68
H168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
InChI=1/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20
Indurgan
Inexium paranova
Inexium paranova (TN)
Inhibitron
Inhipump
LS-185188
LS-7629
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
Lucen
MLS000069373
MLS001076112
MLS001424148
Maybridge4_002645
Mepral
 
Miol
Miracid
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
MolPort-005-943-880
Mopral
Morecon
NCGC00016925-01
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium Control
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
OMEP
OMZ
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
Omeprazole (JAN/USP/INN)
Omeprazole S-form
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prestwick_808
Prilosec
Prilosec (TN)
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
SMR000058847
SPBio_002306
STK623746
Sanamidol
Secrepina
TL8005099
Tedec Ulceral
UNII-KG60484QX9
UNII-N3PA6559FT
UPCMLD-DP075
UPCMLD-DP075:001
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
Victrix
ZINC04693574
ZINC04693575
Zefxon
Zegerid
Zepral
Zimor
Zoltum
esomeprazol
esomeprazole
esomeprazolum
omeprazole
Ésoméprazole
7
Caffeineapproved, NutraceuticalPhase 439658-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethyl-2,6-dioxopurine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert-Pep
Alert-pep
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine (USP)
Caffeine (natural)
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffeinum
Caffine
Cafipel
Caféine
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
DivK1c_000730
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Hycomine
Hycomine Compound
I14-4386
 
IDI1_000730
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stim
Synalgos-Dc
TNP00310
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina
teína
8Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 14185
9Imatinib MesylatePhase 4, Phase 3, Phase 2, Phase 1600123596
10AnestheticsPhase 4, Phase 3, Phase 1, Phase 29596
11Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 13689
12Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 14067
13Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14257
14Pharmaceutical SolutionsPhase 4, Phase 38192
15Neurotransmitter AgentsPhase 4, Phase 3, Phase 118340
16Tranquilizing AgentsPhase 4, Phase 14265
17Phosphodiesterase InhibitorsPhase 41289
18Gastrointestinal AgentsPhase 4, Phase 3, Phase 28402
19Psychotropic DrugsPhase 4, Phase 16430
20Hypnotics and SedativesPhase 4, Phase 12616
21Purinergic P1 Receptor AntagonistsPhase 4360
22Anti-Anxiety AgentsPhase 4, Phase 11885
23Anesthetics, GeneralPhase 4, Phase 3, Phase 12934
24Adjuvants, AnesthesiaPhase 4, Phase 3, Phase 11674
25Immunosuppressive AgentsPhase 4, Phase 1, Phase 213086
26Anesthetics, IntravenousPhase 4, Phase 3, Phase 12538
27Central Nervous System DepressantsPhase 4, Phase 3, Phase 113403
28GABA AgentsPhase 4, Phase 11684
29GABA ModulatorsPhase 4, Phase 1904
30
Erlotinib HydrochloridePhase 4, Phase 1810183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
31Central Nervous System StimulantsPhase 42211
32
Proton pump inhibitorsPhase 4, Phase 11123
Synonyms:
 
PPIs
33AntacidsPhase 41842
34Anti-Ulcer AgentsPhase 41842
35ColaNutraceuticalPhase 4, Phase 3, Phase 2, Phase 11946
36
Bevacizumabapproved, investigationalPhase 3, Phase 2, Phase 12020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
37
Fentanylapproved, illicit, investigational, vet_approvedPhase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
38
Dasatinibapproved, investigationalPhase 3, Phase 2, Phase 1285302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
39
Formaldehydeapproved, vet_approvedPhase 39350-00-0712
Synonyms:
Aldeide formica
Fannoform
Formaldehyde
Formalin
Formalina
Formaline
Formalith
Formic aldehyde
Formol
 
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
Paraformaldehyde
40
MentholapprovedPhase 326062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
41
Histamineapproved, investigationalPhase 3105075614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-(4-imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
4-imidazoleethylamine
5-Imidazoleethylamine
5-imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminoethylglyoxaline
beta-aminoethylimidazole
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
42
CyproheptadineapprovedPhase 320129-03-32913
Synonyms:
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
129-03-3
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
41354-29-4
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-20-08-00500 (Beilstein Handbook Reference)
AC1L1ER8
AKOS004119847
Axoprol
BIDD:GT0324
BPBio1_000096
BPBio1_000155
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
BRN 1685976
BSPBio_000086
Biomol-NT_000131
C06935
CAS-969-33-5
CCRIS 5232
CHEBI:4046
CHEMBL516
CID2913
CYPROHEPTADINE
Ciproheptadina
Ciproheptadina [INN-Spanish]
Ciprovit
Ciprovit (TN)
Cypoheptadine
Cyproheptadiene
Cyproheptadin
Cyproheptadine
 
Cyproheptadine (INN)
Cyproheptadine Hcl
Cyproheptadine [INN:BAN]
Cyproheptadinum
Cyproheptadinum [INN-Latin]
D07765
DB00434
Dibenzosuberonone/Cyproheptadine
Dihexazin
Dronactin
EINECS 204-928-9
Eiproheptadine
Glutodina
HMS2090P20
HSDB 3048
L001016
LS-114933
Lopac-C-6022
Lopac0_000246
MK 141
MolPort-002-507-777
NCGC00015252-01
NCGC00015252-02
NCGC00015252-03
NCGC00015252-09
NCGC00024293-02
NCGC00024293-04
NCGC00024293-05
Oprea1_498140
PDSP1_001229
PDSP2_001213
Periactin
Periactine
Periactinol
Prestwick0_000103
Prestwick1_000103
Prestwick2_000103
Prestwick3_000103
SPBio_002025
STK802098
Tocris-0996
UNII-2YHB6175DO
Viternum
nchembio.559-comp10
43NarcoticsPhase 33646
44
crenolanibPhase 3, Phase 21610366136
Synonyms:
 
CP-868569
crenolanib
45Analgesics, OpioidPhase 33238
46Peripheral Nervous System AgentsPhase 3, Phase 223689
47pancreatic polypeptidePhase 3, Phase 120
48Calcium, DietaryPhase 3, Phase 15713
49AnalgesicsPhase 311733
50Antibodies, MonoclonalPhase 3, Phase 2, Phase 14039

Interventional clinical trials:

(show top 50)    (show all 283)
idNameStatusNCT IDPhase
1Study to the Optimal Duration of Therapy With Oral Angiogenesis InhibitorsUnknown statusNCT00777504Phase 4
2Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerUnknown statusNCT00274885Phase 4
3Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal TumorCompletedNCT00793871Phase 4
4Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT00171977Phase 4
5Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib MesylateCompletedNCT00510354Phase 4
6Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
7The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of RegorafenibRecruitingNCT02800330Phase 4
8Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibActive, not recruitingNCT00756509Phase 4
9Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial TumorsEnrolling by invitationNCT02884154Phase 4
10Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study TerminationNo longer availableNCT01613053Phase 4
11Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino PatientsTerminatedNCT01073644Phase 4
12Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on ImatinibTerminatedNCT00461929Phase 4
13Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal TumorUnknown statusNCT00685828Phase 3
14Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal TumorUnknown statusNCT00103168Phase 3
15A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical TreatmentUnknown statusNCT00812240Phase 3
16A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With ImatinibUnknown statusNCT01694277Phase 3
17Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of RecurrenceUnknown statusNCT02009423Phase 3
18Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By SurgeryCompletedNCT00041197Phase 3
19Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal TumorCompletedNCT00324987Phase 3
20Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal TumorsCompletedNCT00293124Phase 3
21A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)CompletedNCT00075218Phase 3
22Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.CompletedNCT01289028Phase 3
23Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed ConditionsCompletedNCT02103322Phase 2, Phase 3
24Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT01462994Phase 3
25Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and SunitinibCompletedNCT00471328Phase 3
26Rechallenge of Imatinib in GIST Having no Effective TreatmentCompletedNCT01151852Phase 3
27A Study of Nilotinib Versus Imatinib in GIST PatientsCompletedNCT00785785Phase 3
28Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs MaintenanceCompletedNCT00367861Phase 3
29Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)CompletedNCT00116935Phase 3
30Caphosol in Oral Mucositis Due to Targeted TherapyCompletedNCT01265810Phase 3
31Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
32Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative ColitisCompletedNCT00033943Phase 2, Phase 3
33Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)RecruitingNCT02260505Phase 3
34EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELsRecruitingNCT02866045Phase 3
35Randomized Trial of Crenolanib in Subjects With D842V Mutated GISTRecruitingNCT02847429Phase 3
36Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GISTRecruitingNCT02413736Phase 3
37A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHDRecruitingNCT02336230Phase 3
38Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)Active, not recruitingNCT01271712Phase 3
39Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade IndexNot yet recruitingNCT02576080Phase 3
40A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal CancerNot yet recruitingNCT02773524Phase 3
41Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard TherapyNo longer availableNCT01646593Phase 3
42Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib MesylateTerminatedNCT00956072Phase 3
43Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal TumorTerminatedNCT00009906Phase 3
44Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal TumorsTerminatedNCT00372567Phase 3
45Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 MgTerminatedNCT00751036Phase 3
46Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) PatientsTerminatedNCT01031628Phase 3
47Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and SunitinibTerminatedNCT00688766Phase 3
48Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for CancerTerminatedNCT01132547Phase 3
49A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to ImatinibUnknown statusNCT01506336Phase 2
50Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)Unknown statusNCT00290485Phase 2

Search NIH Clinical Center for Gastrointestinal Stromal Tumor


Cochrane evidence based reviews: gastrointestinal stromal tumors

Genetic Tests for Gastrointestinal Stromal Tumor

About this section

Genetic tests related to Gastrointestinal Stromal Tumor:

id Genetic test Affiliating Genes
1 Gastrointestinal Stromal Tumor27 24 KIT, PDGFRA, SDHB

Anatomical Context for Gastrointestinal Stromal Tumor

About this section

MalaCards organs/tissues related to Gastrointestinal Stromal Tumor:

36
Small intestine, Colon, Endothelial, Smooth muscle, Liver, Myeloid, Bone

Publications for Gastrointestinal Stromal Tumor

About this section

Articles related to Gastrointestinal Stromal Tumor:

(show top 50)    (show all 1346)
idTitleAuthorsYear
1
A Novel Curative Treatment Strategy for Patients with Lower Grade Rectal Gastrointestinal Stromal Tumor: Chemoreduction Combined with Transanal Endoscopic Microsurgery. (28358587)
2017
2
Skull Metastasis of Gastric Gastrointestinal Stromal Tumor Successfully Managed by Surgery. (28061498)
2017
3
Duodenal gastrointestinal stromal tumor presenting as pancreatic head mass - a case report. (28523328)
2017
4
Gastrointestinal stromal tumor with a PDGFRA mutation masquerading as gastric plexiform fibromyxoma: A comparative clinicopathological study of two cases. (28356974)
2017
5
Extra-Gastrointestinal Stromal Tumor of Prostate. (28418346)
2017
6
Familial Progressive Hyperpigmentation, Cutaneous Mastocytosis, and Gastrointestinal Stromal Tumor as Clinical Manifestations of Mutations in the c-KIT Receptor Gene. (27981619)
2017
7
Severe bleeding caused by giant gastrointestinal stromal tumor of the jejunum. (28457469)
2017
8
Gastrointestinal stromal tumor presenting as a right adnexal mass with histopathologic correlation. (28494279)
2017
9
Removal of an extraluminal gastric gastrointestinal stromal tumor: the role of submucosal tunneling endoscopic resection. (28068687)
2017
10
Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. (28383355)
2017
11
Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. (28159677)
2017
12
Glomus tumor of the stomach-a tumor that needs to be differentiated from gastrointestinal stromal tumor. (28501534)
2017
13
The Diagnostic and Prognostic Utility of DOG1 Expression on Gastrointestinal Stromal Tumors. (28044310)
2017
14
A Congenital Gastric Anomaly, Masquerading as Gastrointestinal Stromal Tumor. (28056350)
2017
15
An Epithelioid Gastrointestinal Stromal Tumor of the Stomach With Strong Expression of Keratin: Clinicopathologic Correlation and Follow-up Post-Imatinib Therapy. (28362703)
2017
16
Gastrointestinal Stromal Tumor Induced Hypercalcemia. (28484656)
2017
17
Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up. (28083710)
2017
18
Unusual presentation of gastrointestinal stromal tumor. (28377288)
2017
19
A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. (28487491)
2017
20
Primary Extra-Gastrointestinal Stromal Tumor of Mesenteric Root: a Rare Version of a Soft Tissue Tumor Located on a Critical Region. (28367608)
2017
21
BRUNNER GLAND ADENOMA MASQUERADING AS DUODENAL GASTROINTESTINAL STROMAL TUMOR WITH INTUSSUSCEPTION: CASE REPORT. (28489176)
2017
22
Orai1 mediates tumor-promoting store-operated Ca(2+) entry in human gastrointestinal stromal tumors via c-KIT and the extracellular signal-regulated kinase pathway. (28231736)
2017
23
Clinical and pathological characteristics of gastrointestinal stromal tumor (GIST) metastatic to bone. (28488171)
2017
24
How best to manage gastrointestinal stromal tumor. (28439494)
2017
25
Uptake of (123)I-metaiodobenzylguanidine by gastrointestinal stromal tumor. (28447327)
2017
26
Sphincter-saving resection by cluneal arched skin incision for a gastrointestinal stromal tumor (GIST) of the lower rectum: a case report. (28058590)
2017
27
miRNA-218-loaded carboxymethyl chitosan - Tocopherol nanoparticle to suppress the proliferation of gastrointestinal stromal tumor growth. (28024574)
2017
28
Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors. (27864688)
2017
29
Gastrointestinal Stromal Tumor Showing Intense Tracer Uptake on PSMA PET/CT. (28072616)
2017
30
An Intra-Abdominal Desmoid Tumor, Embedded in the Pancreas, Preoperatively Diagnosed as an Extragastric Growing Gastrointestinal Stromal Tumor. (28512414)
2017
31
Concomitant Lung Cancer and Gastrointestinal Stromal Tumor: First Report of Hypoxia Imaging With 18F-FAZA PET/CT. (28525452)
2017
32
Laparoscopy-assisted full-thickness resection of the duodenum for patients with gastrointestinal stromal tumor with ulceration. (28386914)
2017
33
KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors. (26587973)
2016
34
Gain of TP53 Mutation in Imatinib-treated SDH-Deficient Gastrointestinal Stromal Tumor and Clinical Utilization of Targeted Next-generation Sequencing Panel for Therapeutic Decision Support. (28027118)
2016
35
Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments. (27163723)
2016
36
Our experience with laparoscopic partial gastrectomy by the 'lift-and-cut method' for gastric gastrointestinal stromal tumor with maximal preservation of the remnant stomach. (27924391)
2016
37
Gastrointestinal stromal tumor as cause of hepatic mass. (27500151)
2016
38
Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor. (27166665)
2016
39
Perforated Gastrointestinal Stromal Tumor of the Meckel's Diverticulum: a Case Report and Review of Literature. (27994335)
2016
40
Gastrointestinal Stromal Tumor Arising From a Gastric Duplication Cyst. (27144196)
2016
41
Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy. (27546844)
2016
42
PDCD2 and NCoR1 as putative tumor suppressors in gastric gastrointestinal stromal tumors. (26589942)
2016
43
Acute Pancreatitis and Gastroduodenal Intussusception Induced by an Underlying Gastric Gastrointestinal Stromal Tumor: A Case Report. (27104028)
2016
44
Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia. (27149004)
2016
45
Interstitial Cells of Cajal in Deep Esophageal Leiomyoma: Immunohistochemical Mimics of Gastrointestinal Stromal Tumor. (27422468)
2016
46
A Case of a Gastrointestinal Stromal Tumor Diagnosed at the Postpartum Period. (27957364)
2016
47
Long-Term Outcomes after Endoscopic Treatment of Gastric Gastrointestinal Stromal Tumor. (27196737)
2016
48
An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells. (27633918)
2016
49
Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report. (26457546)
2016
50
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. (27456941)
2016

Variations for Gastrointestinal Stromal Tumor

About this section

UniProtKB/Swiss-Prot genetic disease variations for Gastrointestinal Stromal Tumor:

70
id Symbol AA change Variation ID SNP ID
1KITp.Lys550IleVAR_033123rs28933968
2KITp.Val559AlaVAR_033126rs121913517
3KITp.Val559AspVAR_033127rs121913517
4PDGFRAp.Tyr849CysVAR_066474

Clinvar genetic disease variations for Gastrointestinal Stromal Tumor:

5 (show all 95)
id Gene Variation Type Significance SNP ID Assembly Location
1SDHBNM_ 003000.2(SDHB): c.268C> T (p.Arg90Ter)SNVPathogenicrs74315366GRCh37Chr 1, 17359573: 17359573
2SDHBNM_ 003000.2(SDHB): c.590C> G (p.Pro197Arg)SNVPathogenic/ Likely pathogenicrs74315367GRCh37Chr 1, 17350520: 17350520
3SDHBNM_ 003000.2(SDHB): c.725G> A (p.Arg242His)SNVPathogenicrs74315368GRCh37Chr 1, 17349143: 17349143
4SDHBNM_ 003000.2(SDHB): c.79C> T (p.Arg27Ter)SNVPathogenicrs74315369GRCh37Chr 1, 17371377: 17371377
5PDGFRANM_ 006206.5(PDGFRA): c.2525A> T (p.Asp842Val)SNVPathogenicrs121908585GRCh37Chr 4, 55152093: 55152093
6PDGFRANM_ 006206.5(PDGFRA): c.2526_ 2537delCATCATGCATGA (p.Ile843_ Asp846del)deletionPathogenic/ Likely pathogenicrs587776792GRCh38Chr 4, 54285927: 54285938
7PDGFRANM_ 006206.5(PDGFRA): c.2533_ 2544delCATGATTCGAAC (p.His845_ Asn848del)deletionPathogenicrs587776793GRCh37Chr 4, 55152101: 55152112
8PDGFRANM_ 006206.5(PDGFRA): c.1682T> A (p.Val561Asp)SNVPathogenicrs121908586GRCh37Chr 4, 55141036: 55141036
9PDGFRANM_ 006206.5(PDGFRA): c.1681_ 1682insAGAGGG (p.Arg560_ Val561insGluArg)insertionPathogenicrs587776794GRCh38Chr 4, 54274868: 54274869
10PDGFRANM_ 006206.5(PDGFRA): c.1679_ 1693delGGGTCATTGAATCAA (p.Arg560_ Ser564del)deletionPathogenicrs587776795GRCh38Chr 4, 54274866: 54274880
11PDGFRANM_ 006206.5(PDGFRA): c.1696_ 1713del18 (p.Ser566_ Glu571del)deletionPathogenicrs121913271GRCh38Chr 4, 54274883: 54274900
12PDGFRANM_ 006206.5(PDGFRA): c.2536G> T (p.Asp846Tyr)SNVPathogenic/ Likely pathogenicrs121908588GRCh37Chr 4, 55152104: 55152104
13KITNM_ 000222.2(KIT): c.1676_ 1681delTTGTTG (p.Val559_ Val560del)deletionPathogenicrs587776803GRCh38Chr 4, 54727444: 54727449
14KITNM_ 000222.2(KIT): c.2447A> T (p.Asp816Val)SNVPathogenic/ Likely pathogenicrs121913507GRCh37Chr 4, 55599321: 55599321
15KITNM_ 000222.2(KIT): c.1652_ 1666delCCATGTATGAAGTAC (p.Pro551_ Val555del)deletionPathogenicrs587776804GRCh37Chr 4, 55593586: 55593600
16KITKIT, 15-BP DEL/LYS550ILEdeletionPathogenic
17KITNM_ 000222.2(KIT): c.1676T> A (p.Val559Asp)SNVPathogenic/ Likely pathogenicrs121913517GRCh37Chr 4, 55593610: 55593610
18KITNM_ 000222.2(KIT): c.1648_ 1674del27 (p.Lys550_ Lys558del)deletionPathogenicrs121913234GRCh38Chr 4, 54727416: 54727442
19KITNM_ 000222.2(KIT): c.2446G> T (p.Asp816Tyr)SNVPathogenic/ Likely pathogenicrs121913506GRCh37Chr 4, 55599320: 55599320
20KITNM_ 000222.2(KIT): c.2515G> A (p.Glu839Lys)SNVPathogenic/ Likely pathogenicrs121913509GRCh37Chr 4, 55602694: 55602694
21KITNM_ 000222.2(KIT): c.2446G> C (p.Asp816His)SNVPathogenic/ Likely pathogenicrs121913506GRCh37Chr 4, 55599320: 55599320
22KITNM_ 000222.2(KIT): c.1676T> C (p.Val559Ala)SNVPathogenic/ Likely pathogenicrs121913517GRCh37Chr 4, 55593610: 55593610
23KITNM_ 000222.2(KIT): c.1924A> G (p.Lys642Glu)SNVPathogenic/ Likely pathogenicrs121913512GRCh37Chr 4, 55594221: 55594221
24BRAFNM_ 004333.4(BRAF): c.1799T> A (p.Val600Glu)SNVPathogenic/ Likely pathogenicrs113488022GRCh37Chr 7, 140453136: 140453136
25SDHBNM_ 003000.2(SDHB): c.286+2T> ASNVPathogenicrs587781270GRCh37Chr 1, 17359553: 17359553
26SDHBNM_ 003000.2(SDHB): c.689G> A (p.Arg230His)SNVPathogenic/ Likely pathogenicrs587782604GRCh37Chr 1, 17349179: 17349179
27SDHBNM_ 003000.2(SDHB): c.136C> T (p.Arg46Ter)SNVPathogenicrs74315370GRCh37Chr 1, 17371320: 17371320
28SDHBNM_ 003000.2(SDHB): c.72+1G> TSNVPathogenicrs587782703GRCh37Chr 1, 17380442: 17380442
29SDHBNM_ 003000.2(SDHB): c.600G> T (p.Trp200Cys)SNVPathogenicrs397516836GRCh37Chr 1, 17350510: 17350510
30SDHBNM_ 003000.2(SDHB): c.137G> A (p.Arg46Gln)SNVPathogenicrs772551056GRCh37Chr 1, 17371319: 17371319
31SDHBNM_ 003000.2(SDHB): c.380T> G (p.Ile127Ser)SNVPathogenic/ Likely pathogenicrs786201095GRCh37Chr 1, 17355138: 17355138
32SDHBNM_ 003000.2(SDHB): c.418G> T (p.Val140Phe)SNVPathogenic/ Likely pathogenicrs267607032GRCh37Chr 1, 17355100: 17355100
33SDHBNM_ 003000.2(SDHB): c.689G> T (p.Arg230Leu)SNVLikely pathogenicrs587782604GRCh37Chr 1, 17349179: 17349179
34SDHBNM_ 003000.2(SDHB): c.166_ 170delCCTCA (p.Pro56Tyrfs)deletionPathogenicrs786202100GRCh37Chr 1, 17371286: 17371290
35SDHBNM_ 003000.2(SDHB): c.724C> T (p.Arg242Cys)SNVPathogenicrs786203251GRCh37Chr 1, 17349144: 17349144
36KITNM_ 000222.2(KIT): c.1669_ 1674delTGGAAG (p.Trp557_ Lys558del)deletionLikely pathogenicrs869025568GRCh38Chr 4, 54727437: 54727442
37SDHBNM_ 003000.2(SDHB): c.587G> A (p.Cys196Tyr)SNVPathogenicrs876658367GRCh37Chr 1, 17350523: 17350523
38SDHBNM_ 003000.2(SDHB): c.640C> T (p.Gln214Ter)SNVPathogenicrs876658461GRCh37Chr 1, 17350470: 17350470
39SDHBNM_ 003000.2(SDHB): c.-151_ *159deldeletionPathogenicGRCh38Chr 1, 17018722: 17054170
40SDHBNM_ 003000.2(SDHB): c.126delT (p.Phe42Leufs)deletionPathogenicrs878854572GRCh37Chr 1, 17371330: 17371330
41SDHBNM_ 003000.2(SDHB): c.201-2A> CSNVLikely pathogenicrs878854574GRCh37Chr 1, 17359642: 17359642
42SDHBNM_ 003000.2(SDHB): c.271A> T (p.Arg91Ter)SNVPathogenicrs878854575GRCh37Chr 1, 17359570: 17359570
43SDHBNM_ 003000.2(SDHB): c.296G> A (p.Gly99Asp)SNVLikely pathogenicrs878854576GRCh37Chr 1, 17355222: 17355222
44SDHCNM_ 003001.3(SDHC): c.406-?_ *2318+?deldeletionPathogenic
45SDHBNM_ 003000.2(SDHB): c.201-?_ 765+?dupduplicationLikely pathogenic
46SDHBNM_ 003000.2(SDHB): c.423+1G> ASNVPathogenicrs398122805GRCh37Chr 1, 17355094: 17355094
47MTHFRNM_ 005957.4(MTHFR): c.665C> T (p.Ala222Val)SNVdrug responsers1801133GRCh37Chr 1, 11856378: 11856378
48MTHFRNM_ 005957.4(MTHFR): c.1286A> C (p.Glu429Ala)SNVdrug responsers1801131GRCh37Chr 1, 11854476: 11854476
49PDGFRANM_ 006206.5(PDGFRA): c.1977C> A (p.Asn659Lys)SNVPathogenicrs1057519700GRCh37Chr 4, 55144148: 55144148
50PDGFRANM_ 006206.5(PDGFRA): c.1977C> G (p.Asn659Lys)SNVPathogenicrs1057519700GRCh37Chr 4, 55144148: 55144148
51KITNM_ 000222.2(KIT): c.1669T> A (p.Trp557Arg)SNVPathogenic/ Likely pathogenicrs121913235GRCh37Chr 4, 55593603: 55593603
52KITNM_ 000222.2(KIT): c.1669T> C (p.Trp557Arg)SNVPathogenic/ Likely pathogenicrs121913235GRCh38Chr 4, 54727437: 54727437
53KITNM_ 000222.2(KIT): c.1674G> T (p.Lys558Asn)SNVPathogenic/ Likely pathogenicrs200375589GRCh37Chr 4, 55593608: 55593608
54KITNM_ 000222.2(KIT): c.1676T> G (p.Val559Gly)SNVPathogenic/ Likely pathogenicrs121913517GRCh37Chr 4, 55593610: 55593610
55KITNM_ 000222.2(KIT): c.1679T> A (p.Val560Asp)SNVPathogenic/ Likely pathogenicrs121913521GRCh37Chr 4, 55593613: 55593613
56KITNM_ 000222.2(KIT): c.1679T> G (p.Val560Gly)SNVPathogenic/ Likely pathogenicrs121913521GRCh37Chr 4, 55593613: 55593613
57KITNM_ 000222.2(KIT): c.1727T> C (p.Leu576Pro)SNVPathogenic/ Likely pathogenicrs121913513GRCh37Chr 4, 55593661: 55593661
58KITNM_ 000222.2(KIT): c.1961T> C (p.Val654Ala)SNVPathogenic/ Likely pathogenicrs121913523GRCh37Chr 4, 55594258: 55594258
59KITNM_ 000222.2(KIT): c.2465A> T (p.Asn822Ile)SNVPathogenic/ Likely pathogenicrs993022333GRCh37Chr 4, 55599339: 55599339
60KITNM_ 000222.2(KIT): c.2466T> A (p.Asn822Lys)SNVPathogenic/ Likely pathogenicrs121913514GRCh37Chr 4, 55599340: 55599340
61KITNM_ 000222.2(KIT): c.2466T> G (p.Asn822Lys)SNVPathogenic/ Likely pathogenicrs121913514GRCh37Chr 4, 55599340: 55599340
62KITNM_ 000222.2(KIT): c.2485G> C (p.Ala829Pro)SNVPathogenic/ Likely pathogenicrs1057519713GRCh37Chr 4, 55602664: 55602664
63PDGFRANM_ 006206.5(PDGFRA): c.2524_ 2525delGAinsAT (p.Asp842Ile)indelLikely pathogenicrs121913264GRCh37Chr 4, 55152092: 55152093
64KITNM_ 000222.2(KIT): c.1675G> A (p.Val559Ile)SNVLikely pathogenicrs121913520GRCh37Chr 4, 55593609: 55593609
65KITNM_ 000222.2(KIT): c.2009C> T (p.Thr670Ile)SNVLikely pathogenicrs121913516GRCh37Chr 4, 55595519: 55595519
66KITNM_ 000222.2(KIT): c.2467T> G (p.Tyr823Asp)SNVLikely pathogenicrs1057519761GRCh37Chr 4, 55599341: 55599341
67PDGFRANM_ 006206.5(PDGFRA): c.2521_ 2526delAGAGAC (p.Arg841_ Asp842del)deletionLikely pathogenicrs121913269GRCh37Chr 4, 55152089: 55152094
68PDGFRANM_ 006206.5(PDGFRA): c.2524G> T (p.Asp842Tyr)SNVLikely pathogenicrs121913265GRCh37Chr 4, 55152092: 55152092
69PDGFRANM_ 006206.5(PDGFRA): c.2524_ 2532delGACATCATG (p.Asp842_ Met844del)deletionLikely pathogenicrs121913262GRCh37Chr 4, 55152092: 55152100
70PDGFRANM_ 006206.5(PDGFRA): c.2527_ 2538delATCATGCATGAT (p.Ile843_ Asp846del)deletionLikely pathogenicrs121913267GRCh37Chr 4, 55152095: 55152106
71KITNM_ 000222.2(KIT): c.1672A> C (p.Lys558Gln)SNVLikely pathogenicrs1057520031GRCh37Chr 4, 55593606: 55593606
72KITNM_ 000222.2(KIT): c.1670G> C (p.Trp557Ser)SNVLikely pathogenicrs1057520032GRCh37Chr 4, 55593604: 55593604
73KITNM_ 000222.2(KIT): c.1669T> G (p.Trp557Gly)SNVLikely pathogenicrs121913235GRCh37Chr 4, 55593603: 55593603
74KITNM_ 000222.2(KIT): c.1672A> G (p.Lys558Glu)SNVLikely pathogenicrs1057520031GRCh37Chr 4, 55593606: 55593606
75KITNM_ 000222.2(KIT): c.1671G> C (p.Trp557Cys)SNVLikely pathogenicrs1057520033GRCh37Chr 4, 55593605: 55593605
76KITNM_ 000222.2(KIT): c.1679_ 1680delTTinsAA (p.Val560Glu)indelLikely pathogenicrs1057520034GRCh38Chr 4, 54727447: 54727448
77KITNM_ 000222.2(KIT): c.1670_ 1671delGGinsTT (p.Trp557Phe)indelLikely pathogenicrs1057520035GRCh37Chr 4, 55593604: 55593605
78KITNM_ 000222.2(KIT): c.2454delG (p.Asn819Metfs)deletionPathogenicrs1060502521GRCh38Chr 4, 54733162: 54733162
79KITNM_ 000222.2(KIT): c.1735_ 1737delGAT (p.Asp579del)deletionLikely pathogenicrs1060502543GRCh37Chr 4, 55593669: 55593671
80SDHBNM_ 003000.2(SDHB): c.331_ 332delCT (p.Leu111Serfs)deletionPathogenicrs1060503751GRCh38Chr 1, 17028691: 17028692
81SDHBNM_ 003000.2(SDHB): c.620_ 621delTG (p.Leu207Argfs)deletionPathogenicrs1060503752GRCh38Chr 1, 17023994: 17023995
82SDHBNM_ 003000.2(SDHB): c.374C> G (p.Ser125Ter)SNVPathogenicrs786203506GRCh38Chr 1, 17028649: 17028649
83SDHBNM_ 003000.2(SDHB): c.499A> T (p.Lys167Ter)SNVPathogenicrs1060503753GRCh38Chr 1, 17027790: 17027790
84SDHBNM_ 003000.2(SDHB): c.591delC (p.Ser198Alafs)deletionPathogenicrs1060503757GRCh38Chr 1, 17024024: 17024024
85SDHBNM_ 003000.2(SDHB): c.602G> A (p.Trp201Ter)SNVPathogenicrs1060503759GRCh38Chr 1, 17024013: 17024013
86SDHBNM_ 003000.2(SDHB): c.141G> A (p.Trp47Ter)SNVPathogenicrs1060503762GRCh38Chr 1, 17044820: 17044820
87SDHBNM_ 003000.2(SDHB): c.441T> G (p.Tyr147Ter)SNVPathogenicrs1060503763GRCh38Chr 1, 17027848: 17027848
88SDHBNM_ 003000.2(SDHB): c.137G> T (p.Arg46Leu)SNVLikely pathogenicrs772551056GRCh38Chr 1, 17044824: 17044824
89SDHBNM_ 003000.2(SDHB): c.717dupT (p.Leu240Serfs)duplicationLikely pathogenicGRCh38Chr 1, 17022656: 17022656
90SDHBNM_ 003000.2(SDHB): c.22_ 23delTC (p.Ser8Leufs)deletionPathogenicrs1060503767GRCh38Chr 1, 17053997: 17053998
91SDHBNC_ 000001.11: g.(?_ 17044761)_ (17044888_ ?)deldeletionPathogenicGRCh37Chr 1, 17371256: 17371383
92SDHBNM_ 003000.2(SDHB): c.575G> C (p.Cys192Ser)SNVLikely pathogenicrs397516835GRCh37Chr 1, 17350535: 17350535
93KRASNM_ 033360.3(KRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs121913529GRCh37Chr 12, 25398284: 25398284
94FASTKD3; MTRRNM_ 002454.2(MTRR): c.66A> G (p.Ile22Met)SNVdrug responsers1801394GRCh37Chr 5, 7870973: 7870973
95SDHCNM_ 003001.3(SDHC): c.405+1G> ASNVPathogenic/ Likely pathogenicrs587776653GRCh37Chr 1, 161326631: 161326631

Cosmic variations for Gastrointestinal Stromal Tumor:

8 (show top 50)    (show all 125)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM1260KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1679T>Gp.V560G21
2COSM1252KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1676T>Ap.V559D21
3COSM1183KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1654A>Cp.M552L21
4COSM1257KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1679T>Ap.V560D21
5COSM22414PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1977C>Gp.N659K21
6COSM739PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,epithelioidc.1682T>Ap.V561D21
7COSM1216KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1669T>Ap.W557R21
8COSM520KRASsoft tissue,stomach,gastrointestinal stromal tumour,epithelioidc.35G>Tp.G12V21
9COSM1255KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1676T>Cp.V559A21
10COSM1154KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1491G>Ap.V497V21
11COSM736PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2525A>Tp.D842V21
12COSM12708KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2009C>Tp.T670I21
13COSM96893PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2533C>Tp.H845Y21
14COSM476BRAFsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1799T>Ap.V600E21
15COSM18681KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2467T>Gp.Y823D21
16COSM1221KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1669T>Gp.W557G21
17COSM1167KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1650A>Cp.K550N21
18COSM1290KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1727T>Cp.L576P21
19COSM1302KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1769G>Ap.S590N21
20COSM6146PIK3CAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.3137C>Tp.A1046V21
21COSM776PIK3CAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.3140A>Tp.H1047L21
22COSM12706KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1961T>Cp.V654A21
23COSM1227KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1670G>Cp.W557S21
24COSM96885KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1526A>Tp.K509I21
25COSM33903KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1730C>Tp.P577L21
26COSM22416PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1975A>Tp.N659Y21
27COSM17944KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1660G>Ap.E554K21
28COSM96889KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1513A>Cp.N505H21
29COSM96888KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1714G>Ap.D572N21
30COSM22379KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2458G>Cp.D820H21
31COSM1278KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1703A>Gp.Y568C21
32COSM22415PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1977C>Ap.N659K21
33COSM19216KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1674G>Cp.K558N21
34COSM1253KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1676T>Gp.V559G21
35COSM24749KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1690A>Cp.N564H21
36COSM1297KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1751T>Cp.F584S21
37COSM1243KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1674G>Ap.K558K21
38COSM1321KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2466T>Ap.N822K21
39COSM19109KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2464A>Tp.N822Y21
40COSM25065KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1940T>Cp.L647P21
41COSM1166KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1649A>Gp.K550R21
42COSM1219KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1669T>Cp.W557R21
43COSM24750KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1699A>Cp.N567H21
44COSM1184KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1655T>Ap.M552K21
45COSM12709KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2460T>Ap.D820E21
46COSM308543KITsoft tissue,stomach,gastrointestinal stromal tumour,spindle and epithelioidc.1711A>Cp.I571L21
47COSM19325PDGFRAsoft tissue,small intestine,gastrointestinal stromal tumour,spindlec.1765C>Tp.P589S18
48COSM19324PDGFRAsoft tissue,small intestine,gastrointestinal stromal tumour,spindlec.2464C>Ap.R822S18
49COSM133700KITsoft tissue,small intestine,gastrointestinal stromal tumour,spindlec.1671G>Cp.W557C18
50COSM12710KITsoft tissue,small intestine,gastrointestinal stromal tumour,spindlec.2458G>Tp.D820Y18

Copy number variations for Gastrointestinal Stromal Tumor from CNVD:

6 (show top 50)    (show all 117)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
11335211125000000LossGastrointestinal stromal cancer
21335311125000000LossGastrointestinal stromal cancer
31335411125000000LossGastrointestinal stromal cancer
4137661128000000LossGastrointestinal stromal cancer
5142711106334457114964386LossAMPD1Gastrointestinal stromal cancer
6142721106334457114964386LossAP4B1Gastrointestinal stromal cancer
7142731106334457114964386LossBCAS2Gastrointestinal stromal cancer
8164341124300000247249719GainGastrointestinal stromal cancer
9173881142600000147000000GainPEX11BGastrointestinal stromal cancer
102928812300000117600000LossGastrointestinal stromal cancer
113696618412966595422234LossRWDD3Gastrointestinal stromal cancer
1238126199947682100601821LossAGLGastrointestinal stromal cancer
1338127199947682100601821LossHIAT1Gastrointestinal stromal cancer
14445271058788206526558LossFBXO18Gastrointestinal stromal cancer
15445281058788206526558LossPFKFB3Gastrointestinal stromal cancer
16445291058788206526558LossRBM17Gastrointestinal stromal cancer
17458521074900000135534747LossGastrointestinal stromal cancer
184850711153700000Copy numberGastrointestinal stromal cancer
1966050122499108925698435DeletionKRASGastrointestinal stromal cancer
20670671235800000133851895GainGastrointestinal stromal cancer
2170005125702181685836547DeletionRAP1BGastrointestinal stromal cancer
22739001298322858130692602DeletionRANGastrointestinal stromal cancer
237469213110300000115169878LossGastrointestinal stromal cancer
24752471318400000105800000LossGastrointestinal stromal cancer
2575347131919823722523922DeletionLATS2Gastrointestinal stromal cancer
2675669132253620231430096DeletionRNF6Gastrointestinal stromal cancer
2777894134801127654590729DeletionTRIM13Gastrointestinal stromal cancer
2877895134801127654590729DeletionINTS6Gastrointestinal stromal cancer
2978534135252385372250500GainTDRD3Gastrointestinal stromal cancer
3079527137316088193888882GainC13orf7Gastrointestinal stromal cancer
3180767139740402199434703LossCLYBLGastrointestinal stromal cancer
3280768139740402199434703LossSTK24Gastrointestinal stromal cancer
3380769139740402199434703LossTM9SF2Gastrointestinal stromal cancer
34828331417600000107349540LossGastrointestinal stromal cancer
35828341417600000107349540LossGastrointestinal stromal cancer
36830131419100000106368585LossGastrointestinal stromal cancer
37831781419365081106329840LossOXA1LGastrointestinal stromal cancer
38831791419365081106329840LossPPP2R5EGastrointestinal stromal cancer
3984716143394277934940779LossC14orf10Gastrointestinal stromal cancer
4084717143394277934940779LossC14orf24Gastrointestinal stromal cancer
4185081143858582338760942DeletionPNNGastrointestinal stromal cancer
4286405145928447261286479DeletionPPM1AGastrointestinal stromal cancer
4387231147247021673993089LossC14orf168Gastrointestinal stromal cancer
4487232147247021673993089LossPSEN1Gastrointestinal stromal cancer
4587233147247021673993089LossZADH1Gastrointestinal stromal cancer
4687234147247021673993089LossZFYVE1Gastrointestinal stromal cancer
4787235147247021673993089LossZNF410Gastrointestinal stromal cancer
4887381147312625589981048DeletionSEL1LGastrointestinal stromal cancer
4987752147688927477394297LossC14orf133Gastrointestinal stromal cancer
5087753147688927477394297LossC14orf156Gastrointestinal stromal cancer

Expression for genes affiliated with Gastrointestinal Stromal Tumor

About this section
Search GEO for disease gene expression data for Gastrointestinal Stromal Tumor.

Pathways for genes affiliated with Gastrointestinal Stromal Tumor

About this section

Pathways related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

(show all 28)
idSuper pathwaysScoreTop Affiliating Genes
110.2PDGFRA, PDGFRB
2
Show member pathways
10.1KIT, PDGFRA, PDGFRB
310.1ACTC1, KIT, PDGFRA
410.1CD34, KIT, KITLG
510.0CD34, FLT3, KIT
610.0CD34, FLT3, KIT
710.0PDGFRA, S100B, VIM
810.0ACTC1, DES, VIM
9
Show member pathways
10.0KIT, KITLG, PDGFRA, PDGFRB
109.9NTRK3, PDGFRA, PDGFRB, PRKCQ
11
Show member pathways
9.9NTRK3, PDGFRA, PDGFRB, PRKCQ
12
Show member pathways
9.9SDHA, SDHB, SDHC, SDHD
13
Show member pathways
9.9FLT3, KIT, PDGFRB, PRKCQ
149.9CD34, FLT3, KIT, KITLG
159.9CD34, FLT3, KIT, KITLG
169.8FLT3, KIT, KITLG, PDGFRA, PDGFRB
179.8FLT3, KIT, NTRK3, PDGFRA, PDGFRB
189.8HSP90AA1, KIT, KITLG, PDGFRA, PDGFRB
19
Show member pathways
9.8ENO2, SDHA, SDHB, SDHC, SDHD
20
Show member pathways
9.7KIT, KITLG, NTRK3, PDGFRA, PDGFRB, PRKCQ
21
Show member pathways
9.7KIT, KITLG, NTRK3, PDGFRA, PDGFRB, PRKCQ
22
Show member pathways
9.7ACTC1, FLT3, KIT, NTRK3, PDGFRA, PDGFRB
239.7FLT3, HSP90AA1, KIT, KITLG, PDGFRA, PDGFRB
24
Show member pathways
9.6ENO2, MTHFR, SDHA, SDHB, SDHC, SDHD
25
Show member pathways
9.5FLT3, KIT, KITLG, NTRK3, PDGFRA, PDGFRB
26
Show member pathways
9.5FLT3, HSP90AA1, KIT, KITLG, PDGFRA, PDGFRB
27
Show member pathways
9.2ETV1, FLT3, HSP90AA1, KIT, KITLG, NTRK3
28
Show member pathways
9.2FLT3, HSP90AA1, KIT, KITLG, NTRK3, PDGFRA

GO Terms for genes affiliated with Gastrointestinal Stromal Tumor

About this section

Cellular components related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone)GO:000574910.7SDHA, SDHB, SDHC, SDHD
2respiratory chain complex IIGO:004527310.2SDHB, SDHC
3cytoplasmGO:00057379.2ACTC1, CD34, DES, ENO2, FLT3, HSP90AA1
4membraneGO:00160209.0ACTC1, CD34, DES, ENO2, FLT3, HSP90AA1
5plasma membraneGO:00058868.5CD34, DES, ENO2, FLT3, HSP90AA1, KIT

Biological processes related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

(show all 29)
idNameGO IDScoreTop Affiliating Genes
1ectopic germ cell programmed cell deathGO:003523411.0KIT, KITLG
2metanephric glomerular capillary formationGO:007227711.0PDGFRA, PDGFRB
3negative regulation of platelet-derived growth factor receptor-beta signaling pathwayGO:200058711.0PDGFRA, PDGFRB
4myeloid progenitor cell differentiationGO:000231811.0FLT3, KIT
5positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayGO:003809111.0PDGFRA, PDGFRB
6mitochondrial electron transport, succinate to ubiquinoneGO:000612110.9SDHA, SDHD
7cardiac myofibril assemblyGO:005500310.9ACTC1, PDGFRA, PDGFRB
8positive regulation of phospholipase C activityGO:001086310.8KIT, PDGFRA, PDGFRB
9retina vasculature development in camera-type eyeGO:006129810.8PDGFRA, PDGFRB
10succinate metabolic processGO:000610510.8SDHA, SDHB
11hemopoiesisGO:003009710.8CD34, FLT3, KIT
12muscle filament slidingGO:003004910.8ACTC1, DES, VIM
13MAPK cascadeGO:000016510.8KIT, KITLG, PDGFRA, PDGFRB
14phosphatidylinositol phosphorylationGO:004685410.8KIT, KITLG, PDGFRA, PDGFRB
15phosphatidylinositol-mediated signalingGO:004801510.8KIT, KITLG, PDGFRA, PDGFRB
16cell chemotaxisGO:006032610.8KIT, PDGFRA, PDGFRB, PRKCQ
17positive regulation of cell migrationGO:003033510.7KIT, NTRK3, PDGFRA, PDGFRB
18positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.7FLT3, KIT, PDGFRA, PDGFRB
19positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.7FLT3, KIT, PDGFRA, PDGFRB
20positive regulation of MAP kinase activityGO:004340610.7FLT3, KIT, KITLG, PDGFRB
21regulation of phosphatidylinositol 3-kinase signalingGO:001406610.6KIT, KITLG, PDGFRA, PDGFRB
22protein autophosphorylationGO:004677710.5FLT3, KIT, NTRK3, PDGFRA, PDGFRB
23positive regulation of gene expressionGO:001062810.4ACTC1, CD34, KIT, NTRK3, VIM
24phosphorylationGO:001631010.4FLT3, KIT, NTRK3, PDGFRA, PDGFRB, PRKCQ
25peptidyl-tyrosine phosphorylationGO:001810810.4FLT3, HSP90AA1, KIT, NTRK3, PDGFRA, PDGFRB
26protein phosphorylationGO:000646810.3FLT3, KIT, NTRK3, PDGFRA, PDGFRB, PRKCQ
27positive regulation of cell proliferationGO:000828410.3FLT3, KIT, KITLG, NTRK3, PDGFRA, PDGFRB
28transmembrane receptor protein tyrosine kinase signaling pathwayGO:000716910.2FLT3, KIT, NTRK3, PDGFRA, PDGFRB
29tricarboxylic acid cycleGO:00060999.9SDHA, SDHB, SDHC, SDHD

Molecular functions related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1platelet-derived growth factor bindingGO:004840710.9PDGFRA, PDGFRB
2phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:004693410.7KIT, KITLG, PDGFRA, PDGFRB
3electron carrier activityGO:000905510.7SDHA, SDHB, SDHC, SDHD
4succinate dehydrogenase (ubiquinone) activityGO:000817710.6SDHA, SDHB, SDHD
5succinate dehydrogenase activityGO:000010410.5SDHA, SDHC, SDHD
6Ras guanyl-nucleotide exchange factor activityGO:000508810.5KIT, KITLG, PDGFRA, PDGFRB
7ubiquinone bindingGO:004803910.4SDHB, SDHD
8vascular endothelial growth factor bindingGO:003808510.4PDGFRA, PDGFRB
9kinase activityGO:001630110.4FLT3, KIT, NTRK3, PDGFRA, PDGFRB, PRKCQ
10protein kinase activityGO:000467210.3FLT3, KIT, NTRK3, PDGFRA, PDGFRB, PRKCQ
11protein tyrosine kinase activityGO:000471310.2FLT3, HSP90AA1, KIT, NTRK3, PDGFRA, PDGFRB
12vascular endothelial growth factor-activated receptor activityGO:000502110.2FLT3, PDGFRA
13transmembrane receptor protein tyrosine kinase activityGO:000471410.2FLT3, KIT, NTRK3, PDGFRA, PDGFRB
14ATP bindingGO:000552410.1ACTC1, FLT3, HSP90AA1, KIT, NTRK3, PDGFRA

Sources for Gastrointestinal Stromal Tumor

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet